Sign in

CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company

Amylyx Pharmaceuticals, Inc.

Sign in to watch
Ticker
AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
464600503
Phone
617-682-0917
Business address
55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
  1. 4 Option exercise Co-Chief Executive Officer acquired 63,690 shares (option exercise)
  2. 4 Open-market sale Co-Chief Executive Officer sold 18,589 shares at $3.20 ($59,429)
  3. 4 Open-market sale Co-Chief Executive Officer sold 18,589 shares at $3.20 ($59,414)
  4. 4 Open-market sale Chief Medical Officer sold 11,442 shares at $3.20 ($36,559)
  5. 4 Open-market sale Chief Legal Officer sold 8,709 shares at $3.20 ($27,840)
  6. 4 Option exercise Co-Chief Executive Officer acquired 1,857 shares (option exercise)
  7. 4 Option exercise Co-Chief Executive Officer acquired 34,449 shares (option exercise)
  8. 4 Open-market buy Chief Financial Officer bought 40,000 shares at $2.53 ($101,368)
  9. 4 Open-market buy Director bought 50,000 shares at $2.13 ($106,590)
  10. 4/A Option exercise Chief Financial Officer acquired 18,165 shares (option exercise)
  11. 4 Open-market buy Director bought 100,000 shares at $2.20 ($219,800)
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Open-market buy Director bought 5,000 shares at an average $1.89 ($9,436)
  18. 4 Planned sale Chief Legal Officer sold 10,455 shares at $1.88 ($19,654)
  19. 4 Grant or award Chief Financial Officer acquired 91,180 shares (grant or award)
  20. 4 Grant or award Co-Chief Executive Officer acquired 179,850 shares (grant or award)

Page 5 of 11 · 207 filings